Trials
4 active
11 in total · 5 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- Tested for
- Immune Thrombocytopenic Purpura (ITP) (2 trials), Kidney Disease, Antibody-Mediated Rejection (AMR)
- Main trialPhase 3
- “Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously \[SC\]), is effective in keeping the platelet count of adults with ITP stable when compared to a placebo. A placebo looks like medicine but doesn't have any active ingredients in it. The participants will be treated with mezagitamab for up to 6 months. During the…”In the company’s words, NCT06722235 on ClinicalTrials.gov
- Other names
- TAK-079
Other drugs for Immune Thrombocytopenic Purpura (ITP)
- RilzabrutinibSanofi · Phase 3
- Human immunoglobulinGrand Shuyang Life Sciences (Chengdu) Co., Ltd. · Phase 3
- Kedrion IVIG 10%Kedrion S.p.A. · Phase 3
- TQB3473Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Efgartigimodargenx · Phase 3
- QL0911Qilu Pharmaceutical · Phase 3
Coming up4
- 16 Mar 2028Phase 3 trial completes · ClinicalTrials.gov
- 7 Sep 2028Phase 3 trial completes · ClinicalTrials.gov
- 15 Jan 2029Phase 2 trial completes · ClinicalTrials.gov
- 29 Jul 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 16 Mar 2028 | A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia | |
| Phase 3Recruiting | 7 Sep 2028 | A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy | |
| Phase 3Recruiting | 29 Jul 2029 | A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia | |
| Phase 2Recruiting | 15 Jan 2029 | A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant | |
| Phase 2Completed | 12 Jul 2022 | A Study of TAK-079 in People With Generalized Myasthenia Gravis | |
| Phase 2Completed | 29 Apr 2024 | A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia | |
| Phase 1/2Completed | 28 Jan 2022 | A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) | |
| Phase 1/2Terminated | 2 Aug 2023 | A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) | |
| Phase 1Completed | 4 Nov 2021 | A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE) | |
| Phase 1Completed | 15 Dec 2025 | A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy | |
| Phase 1Completed | 25 Mar 2026 | A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026